Obsidian Therapeutics

OBX (NasdaqCM)

Obsidian Therapeutics is a clinical-stage biotechnology company focused on engineered cell and gene therapies. It is developing therapies such as OBX-115, currently in trials for advanced solid tumors, melanoma, and relapsed/refractory non-small cell lung cancer. Its Cytodriver platform modulates protein function with FDA-approved small molecules, and it advances mbIL15-enhanced tumor-infiltrating lymphocyte (TIL) therapies to boost persistence, activity, and safety. Access is via trials; the company collaborates with partners. Founded 2015, Cambridge, MA.